Wunderle, Marius https://orcid.org/0009-0007-7280-7697
Heindl, Felix
Behrens, Annika S.
Häberle, Lothar
Hack, Carolin C.
Heusinger, Katharina
Huebner, Hanna
Gass, Paul
Ruebner, Matthias
Schulz-Wendtland, Rüdiger
Erber, Ramona
Hartmann, Arndt
Beckmann, Matthias W.
Dougall, William C.
Press, Michael F.
Fasching, Peter A. https://orcid.org/0000-0003-4885-8471
Emons, Julius
Funding for this research was provided by:
Bayerisch-Kalifornisches Hochschulzentrum
Breast Cancer Research Foundation (BCRF-22-132)
California Breast Cancer Research Program (BCRP 12IB-0155)
Deutsche Krebshilfe
Universitätsklinikum Erlangen
Article History
Received: 12 January 2024
Accepted: 24 March 2024
First Online: 5 June 2024
Declarations
:
: <b>AH</b> has had an advisory role and has received honoraria from Abbvie, Agilent, AstraZeneca, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Jansen-Cilag, Lilly, MSD, Pfizer, Qiagen, and Roche. <b>RE</b> has received honoraria from AstraZeneca, BioNTech, Diaceutics, Eisai, MEDAC, Mindpeak, Novartis, Pfizer, Roche, and Veracyte (PROCURE). The institution of <b>AH</b> and <b>RE</b> conducts research for AstraZeneca, Biocartis, BioNTech, Cepheid, Gilead, Janssen-Cilag, Mindpeak, MSD, NanoString Technologies, Novartis, palleos healthcare, Owkin, Roche, and ZytoVision. <b>CCH</b> has received honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, MSD, Novartis, Pfizer, and Roche. <b>JE</b> has received honoraria from Eisai, Novartis, and Pfizer. <b>PAF</b> has received honoraria from Agendia, AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Gilead, Hexal, Lilly, MacroGenics, Merck Sharp and Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Seattle Genetics, and received grant support from BioNTech and Cepheid. <b>PG</b> has received honoraria from AstraZeneca, MSD, and Novartis. <b>MFP</b> has received consulting fees from AstraZeneca, Curio Science, Eli Lilly & Company, Lilly USA, LLC, Merck & Co, Novartis Pharmaceuticals Corporation, and Zymeworks Inc, honoraria for speaking engagements from Physicians’ Education Resource®, LLC (PER®) and Medscape, and he reports institutional support from TORL BioTherapeutics LLC. <b>WCD</b> is a member of the EpimAb Biotherapeutics scientific advisory board and holds patents related to the Receptor Activator of Nuclear Factor-κ B Ligand (RANKL) pathway. The other authors declare no conflict of interest.
: This study was approved by the ethics committee of the Faculty of Medicine at Friedrich-Alexander-Universität Erlangen-Nürnberg (reference numbers 2700 and 297_17 BC). All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.